A growing body of research highlights the broader benefits of human papillomavirus (HPV) vaccination beyond its long-standing focus on cervical cancer prevention. A recent large-scale retrospective cohort study published in JAMA Oncology provides compelling evidence that vaccinating boys and young men substantially lowers their risk of developing HPV-related cancers.
Study Overview and Key Findings
Researchers in Japan analyzed health data from more than 1 million males aged 9 to 26 years, comparing outcomes between approximately 510,000 vaccinated individuals and an equal number of unvaccinated peers. Over a follow-up period of up to 10 years, investigators found that receiving at least one dose of the nine-valent HPV vaccine was associated with a markedly reduced risk of HPV-related cancers.
Overall, vaccinated participants experienced about a 46% lower risk compared with those who were not vaccinated. When analyzed by age at vaccination, the protective effect remained consistent. Males immunized between ages 9 and 14 saw roughly a 42% reduction in risk, while those vaccinated between ages 15 and 26 experienced about a 50% reduction. These findings suggest that meaningful protection is achievable even when vaccination occurs later in adolescence or early adulthood.
Expanding the Scope of Prevention
HPV is widely recognized for its role in cervical cancer, but it also contributes to multiple malignancies affecting men, including cancers of the head and neck, anus, and penis. Historically, vaccination campaigns have primarily targeted females due to the burden of cervical cancer. However, this new evidence reinforces the need to broaden prevention strategies.
Unlike earlier investigations that often focused on adult populations, where prior HPV exposure may blunt vaccine effectiveness, this study underscores the benefits of vaccination across a wider male age range, including those vaccinated after early adolescence.
Policy Implications
The findings carry important implications for public health policy. Many countries still prioritize HPV vaccination for females, and global uptake among males remains comparatively low. The authors argue that equitable access to HPV vaccination, regardless of sex, could significantly reduce the overall burden of HPV-related cancers.
In contrast, the United States has seen higher uptake among boys, with roughly three-quarters of adolescent males receiving at least one vaccine dose as of 2024. The study supports expanding similar efforts worldwide and strengthening messaging around the benefits of vaccination for both sexes.
Study Limitations
While the results are encouraging, the researchers acknowledge several limitations. The study relied on administrative health data, which may include inaccuracies in diagnosis coding. Additionally, vaccination records outside participating health systems may not have been fully captured. The analysis also could not account for behavioral risk factors, such as sexual activity, which may influence HPV exposure.
Conclusion
Despite these limitations, the study adds to mounting evidence that HPV vaccination provides significant protective benefits for males. By demonstrating a substantial reduction in cancer risk, the findings support a shift toward more inclusive vaccination programs that target both boys and girls. Expanding access and uptake could play a critical role in reducing HPV-related cancers globally.
